This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor.
—I read with interest the article by Dr Strom and colleagues1 regarding parental ketorolac and the risks of gastrointestinal and operative site bleeding. While I acknowledge the necessity of publishing such a postmarketing surveillance study, the conclusions are concerning.In particular, this article seems to indicate that there is a low risk of operative site bleeding with this medication. It is important to point out a study2 in the ear, nose, and throat literature that demonstrated an approximately 5-fold increase in postoperative hemorrhage in patients who had received ketorolac perioperatively for tonsillectomy and adenoidectomy vs control patients. That article2 indicates the necessity of double-blinded studies of this drug for specific types of surgical procedures. Ketorolac appears to prompt bleeding after surgery performed on mucosal surfaces (ie, nasal, sinus, and tonsil and adenoid procedures). I believe a warning should be given on labelling for this
Gumprecht T. Risk of Operative Site Bleeding With Parenteral Ketorolac. JAMA. 1996;276(5):372. doi:10.1001/jama.1996.03540050032014